Fall is finally here, and with it comes the onset of flu season. The flu is a difficult illness for everyone, but for cancer patients, it can be devastating. It is especially challenging in this year that has already taxed everyone with the uncertainty of COVID-19.
A cancer diagnosis has a significant impact on patients, caregivers and their families. It is normal for someone diagnosed with GIST to feel a whole host of emotions ranging from anger to fear, sadness and anxiety about the future.
Sara Rothschild, VP Programs and Services at the LRG, attended an executive education program at the Harvard Business School which brought together leaders from the health care, scientific, technological, and business communities to speed progress and drive cures.
Fall is finally here, and with it comes the onset of Flu Season. Flu is a difficult illness for everyone, but for cancer patients, it can be devastating. On average, 5 percent to 20 [...]
A story about a cancer survivor recently appeared in the Washington Post: “This is not the end; Using immunotherapy and a genetic glitch to give cancer patients hope”. The story is about a young [...]
Navigating the waters of medical treatment can be not only confusing, but also potentially deadly. According to the Agency for Healthcare Research and Quality, one in seven Medicare patients in hospitals experiences a medical error. [...]
A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]
A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]
Dr. Chris Corless In August, the LRG Webcast Series presented “Mutational Analysis of GISTs: How, When and Why.” Dr. Christopher Corless of Oregon Health and Science University (OHSU) presented the hour- long [...]
A recent study in JAMA Oncology found that patients who undergo primary GIST resection might not receive the optimal recommended duration of adjuvant therapy, which can impact their recurrence-free survival (RFS). The study was [...]
